Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations

Analyze the Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations Among Patients With Uncontrolled Asthma Receiving High Dose Inhaled Corticosteroids

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01460862

Enrollment

Registered

2011-10-27

Start date

2011-05-31

Completion date

2011-05-31

Last updated

2021-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma, Omalizumab

Brief summary

A retrospective database analysis to evaluate the impact of omalizumab on the use of corticosteroid, emergency-department visits and hospitalizations among patients with uncontrolled asthma and using high-dose Inhaled Corticosteroids (ICS) prior to initiating omalizumab.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

* ≥12 years of age with a documented Cystic fibrosis (CF) diagnosis, * on Long acting Beta antagonist- Inhaled Corticosteroid (LABA-ICS) at baseline, * uncontrolled asthma at baseline.

Exclusion criteria

Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame
Frequency of emergency-department visits and hospitalizations	12 months

Outcome results